Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* A male or female between, and including, 12 and 14 months of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Vaccination records showing the completion of the full primary vaccination schedule with Prevenar 13 and Diphtheria, Tetanus and Pertussis (DTP) containing vaccine according to local recommendations at least 5 months before the study entry.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine or planned use during the study period.~* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.~* Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the dose of vaccines, with the exception of a licensed inactivated influenza vaccine. Measles, Mumps Rubella (MMR) vaccine or Measles Mumps Rubella and Varicella (MMRV) vaccine can be co-administered with MenACWY-TT and/or Prevenar 13. A DTPa containing vaccine can be administered after the last blood sampling (at Visit 2 or 4 depending on the group).~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).~* Previous vaccination against Neisseria meningitidis.~* Previous booster vaccination against Streptococcus pneumoniae.~* Previous booster vaccination against Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis.~* History of meningococcal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing required)\*~  * Note: With the exception of HIV rapid testing which will be done for subjects in South Africa.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity, including to diphtheria toxoid, likely to be exacerbated by any component of the vaccines.~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures, including Guillain-Barré syndrome (GBS). History of a simple, single febrile seizure is permitted.~* Acute disease and/or fever at the time of enrollment.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 14 Months
- Healthy Volunteers: t

Study Arms:
- ACWY1d group (Type: EXPERIMENTAL): Subjects will receive 1 dose of the MenACWY-TT vaccine
- ACWY2d group (Type: EXPERIMENTAL): Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
- Co-ad group (Type: EXPERIMENTAL): Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
- PCV-13 group (Type: ACTIVE_COMPARATOR): Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete